Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Wholesalers Hails Gilead Ambition to Unearth More Hep C Patients through Collaboration
October 26, 2016
- Mitsubishi Tanabe Lifts Earnings Outlook on Simponi, Vaccines
October 26, 2016
- Prof. Yamanaka Eager to Bridge Valley of Death through Takeda Collaboration
October 25, 2016
- Astellas Wins Xtandi Label Update in US for PFS Extension
October 25, 2016
- Sunovion Completes Acquisition of Cynapsus
October 25, 2016
- Shionogi Ups Earnings Forecast for April-September
October 25, 2016
- Ono Files Patent Infringement Suit over Keytruda
October 25, 2016
- Nihon Generic Takes Over 3 Brands from MSD
October 24, 2016
- Prasugrel Disappoints in PIII Study for Ischemic Cerebrovascular Disease
October 24, 2016
- 295 Staffers Applied for Voluntary Redundancy: Sumitomo Dainippon
October 24, 2016
- Daiichi Sankyo Stops Patient Enrollment for Pexidartinib PIII, but Continues Study
October 24, 2016
- Oncolys, DNA Chip Research Team Up to Study Potential of TelomeScan as Companion Diagnostic for CRPC
October 24, 2016
- Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
- Janssen Files Anti-IL-6 Antibody Sirukumab for RA
October 21, 2016
- Humira Biosimilar Hits Primary Endpoint in Global PIII: Fujifilm, Kyowa Kirin
October 20, 2016
- Kaketsuken’s Biz Transfer Talks Fall Apart, but Minister Nixes Its Continued Operations
October 20, 2016
- Astellas Calls Off Biz Transfer Talks with Kaketsuken
October 19, 2016
- UK’s Clinigen Launches Japan Operations with Takeover of Foscavir
October 19, 2016
- Kaketsuken Denies Unauthorized Manufacturing or Cover-up, Blames Ambiguity in Approval Doc
October 19, 2016
- Entyvio’s Real-World Data Support Trial Results: Takeda
October 18, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…